Angelini Pharma And JCR Announce Global Collaboration For Development And Commercialization Of Novel Biologic Therapies In Epilepsy
11/05/2023 08:03
May 11 (Reuters) - JCR Pharmaceuticals Co Ltd 4552.T :
* JCR PHARMACEUTICALS CO LTD - ANGELINI PHARMA AND JCR
ANNOUNCE
GLOBAL COLLABORATION FOR DEVELOPMENT AND COMMERCIALIZATION OF
NOVEL BIOLOGIC THERAPIES IN EPILEPSY
Source text for Eikon: ID:nTSqk8a35e
Further company coverage: 4552.T
Recent news on JCR Pharmaceuticals
See all newsBrief: JCR Pharmaceuticals Receives Marketing Authorization In Kuwait For Izcargo
Italfarmaco And Jcr Pharmaceuticals Enter Into Exclusive License Agreement For Jr-141 In United States, Europe, And Latin America
Brief: Jcr Pharmaceuticals Receives Orphan Drug Designation For Givinostat In Japan
Brief: Medipal & JCR Dose First Patient In Global Phase I/II Trial OF JR-446 For Mucopolysaccharidosis Type IIIB
Table: Jcr Pharmaceuticals -Q1 group results